866-997-4948(US-Canada Toll Free)

Soft Tissue Sarcoma Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Oct 2012

Category :

Oncology

No. of Pages : 312 Pages


Soft Tissue Sarcoma Pipeline Review, H2 2012

Global Markets Directs, 'Soft Tissue Sarcoma Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Soft Tissue Sarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma. Soft Tissue Sarcoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Soft Tissue Sarcoma.
  • A review of the Soft Tissue Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Soft Tissue Sarcoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Soft Tissue Sarcoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Soft Tissue Sarcoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Soft Tissue Sarcoma Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Soft Tissue Sarcoma 11
Soft Tissue Sarcoma Therapeutics under Development by Companies 13
Soft Tissue Sarcoma Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 21
Comparative Analysis 21
Mid Clinical Stage Products 22
Comparative Analysis 22
Early Clinical Stage Products 23
Comparative Analysis 23
Pre-Clinical Stage Products 24
Comparative Analysis 24
Soft Tissue Sarcoma Therapeutics Products under Development by Companies 25
Soft Tissue Sarcoma Therapeutics Products under Investigation by Universities/Institutes 26
Companies Involved in Soft Tissue Sarcoma Therapeutics Development 32
Bristol-Myers Squibb Company 32
Genzyme Corporation 33
Johnson & Johnson 34
F. Hoffmann-La Roche Ltd. 35
Amgen Inc. 36
Sanofi-Aventis 37
Eli Lilly and Company 38
GlaxoSmithKline plc 39
Merck & Co., Inc. 40
Infinity Pharmaceuticals, Inc. 41
Prolexys Pharmaceuticals, Inc. 42
ZIOPHARM Oncology, Inc. 43
Auxilium Pharmaceuticals, Inc. 44
Eisai Co., Ltd. 45
Pfizer Inc. 46
Cell Therapeutics, Inc. 47
Oncolytics Biotech Inc. 48
ARQULE, INC 49
TopoTarget A/S 50
CytRx Corporation 51
Threshold Pharmaceuticals, Inc. 52
Nanobiotix 53
Azaya Therapeutics, Inc. 54
GP Pharm, S.A. 55
MolMed S.p.A. 56
PharmaMar, S.A. 57
Epeius Biotechnologies Corporation 58
Soft Tissue Sarcoma Therapeutics Assessment 59
Assessment by Monotherapy Products 59
Assessment by Combination Products 60
Assessment by Route of Administration 61
Assessment by Molecule Type 63
Drug Profiles 66
eribulin mesylate - Drug Profile 66
brivanib alaninate - Drug Profile 68
ombrabulin - Drug Profile 70
cixutumumab - Drug Profile 72
retaspimycin hydrochloride - Drug Profile 73
collagenase clostridium histolyticum - Drug Profile 75
brostallicin - Drug Profile 78
ridaforolimus - Drug Profile 80
docetaxel - Drug Profile 83
PRLX-93936 - Drug Profile 85
ganitumab - Drug Profile 86
aldoxorubicin - Drug Profile 88
cereolysin - Drug Profile 90
palifosfamide - Drug Profile 92
NGR-hTNF + Doxorubicin - Drug Profile 93
alanosine - Drug Profile 96
tivantinib - Drug Profile 97
Belinostat + Doxorubicin - Drug Profile 99
NBTXR-3 - Drug Profile 100
trabectedin - Drug Profile 102
Doxorubicin + Ifosfamide - Drug Profile 104
trabectedin - Drug Profile 105
sunitinib malate - Drug Profile 106
Rexin-G - Drug Profile 107
Sorafenib + Epirubicin + Ifosfamide - Drug Profile 109
Gemcitabine + Docetaxel + Bevacizumab - Drug Profile 111
Torisel + Doxil - Drug Profile 113
imatinib mesylate - Drug Profile 114
IMC-A12 + Doxorubicin - Drug Profile 116
LBH589 + Nexavar - Drug Profile 118
Doxorubicin + Ifosfamide - Drug Profile 119
Sunitinib + Radiation Therapy - Drug Profile 120
sorafenib tosylate - Drug Profile 122
trofosfamide - Drug Profile 123
sorafenib tosylate - Drug Profile 124
vincristine sulfate - Drug Profile 125
thalidomide - Drug Profile 126
Ifosfamide + Doxorubicin + Filgrastim - Drug Profile 128
Pegfilgrastim + Docetaxel + Gemcitabine - Drug Profile 130
Bevacizumab + Filgrastim + Docetaxel + Gemcitabine - Drug Profile 132
saracatinib - Drug Profile 134
cediranib maleate - Drug Profile 135
Gemcitabine + Trabectedin - Drug Profile 137
ixabepilone - Drug Profile 138
Doxorubicin + Strontium chloride Sr 89 - Drug Profile 140
Cisplatin + Vinblastin - Drug Profile 142
Gemcitabine + Docetaxel + Filgrastim + Pegfilgrastim - Drug Profile 143
Ifosfamide + Doxorubicin - Drug Profile 145
Gemcitabine + Docetaxel + G-CSF - Drug Profile 146
imatinib mesylate - Drug Profile 147
imatinib mesylate - Drug Profile 149
PD-0332991 - Drug Profile 151
Ombrabulin + Cisplatin - Drug Profile 153
palifosfamide + doxorubicin - Drug Profile 154
Yondelis + DOXIL - Drug Profile 156
TH-302 + Doxorubicin - Drug Profile 157
brostallicin - Drug Profile 159
Nexavar + Dacarbazine - Drug Profile 161
dacarbazine - Drug Profile 162
Bevacizumab + Radiation Therapy - Drug Profile 163
Filgrastim + Pegfilgrastim + Docetaxel + Doxorubicin Hydrochloride + Gemcitabine Hydrochloride - Drug Profile 165
Ifosfamide + Adriamycin + G-CSF - Drug Profile 167
Ifosfamide + Adriamycin + G-CSF - Drug Profile 168
rosiglitazone maleate - Drug Profile 169
perifosine - Drug Profile 170
temsirolimus - Drug Profile 171
AMG-655 + Doxorubicin - Drug Profile 172
ifosfamide - Drug Profile 173
alvocidib - Drug Profile 174
Trofosfamide + Idarubicin + Etoposide - Drug Profile 175
exatecan mesylate - Drug Profile 176
Filgrastim + Doxorubicin + Ifosfamide + Radiation Therapy - Drug Profile 177
Cisplatin + Doxorubicin + Radiotherapy - Drug Profile 179
axitinib - Drug Profile 181
Gemcitabine + Docetaxel - Drug Profile 182
Vorinostat + Bortezomib - Drug Profile 184
pazopanib hydrochloride - Drug Profile 185
Trabectedin + Doxorubicin - Drug Profile 186
Sunitinib + Radiation Therapy - Drug Profile 187
Dacarbazine + Bortezomib - Drug Profile 188
paclitaxel - Drug Profile 189
doxorubicin - Drug Profile 192
Caffeine + Cisplatin - Drug Profile 193
pazopanib hydrochloride - Drug Profile 194
plerixafor - Drug Profile 197
trabectedin - Drug Profile 199
trabectedin - Drug Profile 201
Ifosfamide + Adriamycin - Drug Profile 203
AZD6244 + Temsirolimus - Drug Profile 204
selumetinib sulfate - Drug Profile 205
Temsirolimus + Valproic Acid - Drug Profile 206
Filgrastim + Dacarbazine + Doxorubicin + Ifosfamide + Thalidomide - Drug Profile 207
Filgrastim + Dacarbazine + Doxorubicin + Ifosfamide + Thalidomide - Drug Profile 209
Doxorubicin + Radiation Therapy - Drug Profile 211
New Castle Disease Virus - HUJ Oncolytic Virus - Drug Profile 212
CCI-779 + IMC-A12 - Drug Profile 213
cisplatin - Drug Profile 215
Autologous Dendritic Cells + Radiation Therapy - Drug Profile 217
Celebrex + Radiation Therapy - Drug Profile 218
Cisplatin + Doxorubicin - Drug Profile 219
Doxorubicin + Ifosfamide + Radiation Therapy - Drug Profile 220
trabectedin - Drug Profile 222
panobinostat - Drug Profile 223
Caelyx + Ifosfamide - Drug Profile 224
vorinostat - Drug Profile 225
everolimus - Drug Profile 226
Adriamycin + Vindesine - Drug Profile 227
Cyclophosphamide + Adriamycin - Drug Profile 229
WT-1 Immunotherapy - Drug Profile 230
amrubicin - Drug Profile 231
doxorubicin - Drug Profile 232
Everolimus + Imatinib Mesylate - Drug Profile 233
trabectedin - Drug Profile 234
Ifosfamide + Radiation Therapy - Drug Profile 235
Doxorubicin + Ifosfamide - Drug Profile 236
Temozolomide + Proton Therapy - Drug Profile 237
Etoposide + Carboplatin + Cyclophosphamide + Mesna + Melphalan + Tandem Peripheral Blood Stem Cell - Drug Profile 238
Avastin + Standard Chemotherapy - Drug Profile 240
Olaratumab + Doxorubicin - Drug Profile 242
trofosfamide - Drug Profile 243
cediranib maleate - Drug Profile 244
Gemcitabine + Dacarbazine - Drug Profile 245
Taxotere + Irinotecan - Drug Profile 246
Gemcitabine + Docetaxel + Pazopanib - Drug Profile 247
Gemcitabine + Pazopanib - Drug Profile 249
NOV110501 - Drug Profile 250
thiabendazole - Drug Profile 251
Soft Tissue Sarcoma Therapeutics Drug Profile Updates 252
Soft Tissue Sarcoma Therapeutics Discontinued Products 286
Soft Tissue Sarcoma Therapeutics - Dormant Products 287
Soft Tissue Sarcoma Product Development Milestones 295
Featured News & Press Releases 295

Appendix 302
Methodology 302
Coverage 302
Secondary Research 302
Primary Research 302
Expert Panel Validation 302
Contact Us 303
Disclaimer 303

List of Table


Number of Products Under Development for Soft Tissue Sarcoma, H2 2012 20
Products under Development for Soft Tissue Sarcoma Comparative Analysis, H2 2012 21
Number of Products under Development by Companies, H2 2012 23
Number of Products under Development by Companies, H2 2012 (Contd..1) 24
Number of Products under Investigation by Universities/Institutes, H2 2012 26
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 27
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 28
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 29
Comparative Analysis by Late Stage Development, H2 2012 30
Comparative Analysis by Mid Clinical Stage Development, H2 2012 31
Comparative Analysis by Early Clinical Stage Development, H2 2012 32
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 33
Products under Development by Companies, H2 2012 34
Products under Investigation by Universities/Institutes, H2 2012 35
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 36
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 37
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 38
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 39
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 40
Bristol-Myers Squibb Company, H2 2012 41
Genzyme Corporation, H2 2012 42
Johnson & Johnson, H2 2012 43
F. Hoffmann-La Roche Ltd., H2 2012 44
Amgen Inc., H2 2012 45
Sanofi-Aventis, H2 2012 46
Eli Lilly and Company, H2 2012 47
GlaxoSmithKline plc, H2 2012 48
Merck & Co., Inc., H2 2012 49
Infinity Pharmaceuticals, Inc., H2 2012 50
Prolexys Pharmaceuticals, Inc., H2 2012 51
ZIOPHARM Oncology, Inc., H2 2012 52
Auxilium Pharmaceuticals, Inc., H2 2012 53
Eisai Co., Ltd., H2 2012 54
Pfizer Inc., H2 2012 55
Cell Therapeutics, Inc., H2 2012 56
Oncolytics Biotech Inc., H2 2012 57
ARQULE, INC, H2 2012 58
TopoTarget A/S, H2 2012 59
CytRx Corporation, H2 2012 60
Threshold Pharmaceuticals, Inc., H2 2012 61
Nanobiotix, H2 2012 62
Azaya Therapeutics, Inc., H2 2012 63
GP Pharm, S.A., H2 2012 64
MolMed S.p.A., H2 2012 65
PharmaMar, S.A., H2 2012 66
Epeius Biotechnologies Corporation, H2 2012 67
Assessment by Monotherapy Products, H2 2012 68
Assessment by Combination Products, H2 2012 69
Assessment by Stage and Route of Administration, H2 2012 71
Assessment by Stage and Molecule Type, H2 2012 74
Soft Tissue Sarcoma Therapeutics Drug Profile Updates 261
Soft Tissue Sarcoma Therapeutics Discontinued Products 295
Soft Tissue Sarcoma Therapeutics Dormant Products 296
Soft Tissue Sarcoma Therapeutics Dormant Products (Contd..1) 297
Soft Tissue Sarcoma Therapeutics Dormant Products (Contd..2) 298
Soft Tissue Sarcoma Therapeutics Dormant Products (Contd..3) 299
Soft Tissue Sarcoma Therapeutics Dormant Products (Contd..4) 300
Soft Tissue Sarcoma Therapeutics Dormant Products (Contd..5) 301
Soft Tissue Sarcoma Therapeutics Dormant Products (Contd..6) 302
Soft Tissue Sarcoma Therapeutics Dormant Products (Contd..7) 303

List of Chart


Number of Products under Development for Soft Tissue Sarcoma, H2 2012 20
Products under Development for Soft Tissue Sarcoma Comparative Analysis, H2 2012 21
Products under Development by Companies, H2 2012 22
Products under Investigation by Universities/Institutes, H2 2012 25
Late Stage Products, H2 2012 30
Mid Clinical Stage Products, H2 2012 31
Early Clinical Stage Products, H2 2012 32
Pre-Clinical Stage Products, H2 2012 33
Assessment by Monotherapy Products, H2 2012 68
Assessment by Combination Products, H2 2012 69
Assessment by Route of Administration, H2 2012 70
Assessment by Stage and Route of Administration, H2 2012 71
Assessment by Molecule Type, H2 2012 72
Assessment by Stage and Molecule Type, H2 2012 73

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *